Stocks · News reference
Niagen Bioscience Receives FDA Rare Pediatric Disease Designation For Its Drug Candidate NB4168 For The Treatment Of Ataxia Telangiectasia
NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Niagen Bioscience Announces Availability Of Its Healthy-Aging NAD+ Supplement Tru Niagen On Walmart.com
The launch expands access to Tru Niagen through one of the country’s largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven, science-backed NAD+ supplement to
Niagen Bioscience Says It Expects Full-Year Ingredient Business Below Prior Year As Commercial Partners Face More Competitive Market; Sees Niagen Plus And New Skincare Partnerships Contributing Beginning 2027
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001386570/000138657026000043/cdcx-20260630.htm
Niagen Bioscience Widens FY2026 Sales Guidance of $138.982M-$145.299M vs $141.072M Est
Niagen Bioscience (NASDAQ:NAGE) widens FY2026 sales outlook from $138.982 million-$145.299 million to $138.982 million-$145.299 million vs $141.072 million estimate.